Skip to content

Cytokinetics CYTK Debt Conversion Expense

Discontinued — last reported Q3 '25

Debt Conversion Expense at other companies

Antero Resources logo
Antero ResourcesAR
$288K
Antero Resources logo
Antero ResourcesAR
$288K
Booking Holdings Inc. logo
Booking Holdings Inc.BKNG
$0+100%
Applied Digital logo
Applied DigitalAPLD
$0
Synopsys logo
SynopsysSNPS
Semtech logo
SemtechSMTC

Other financials

Income statement

See full
Revenue$19.4M+1,126%
Operating income-$183.6M-18.0%
Net income-$206.0M-27.7%
EPS (diluted)-$1.67-22.8%

Balance sheet

See full
Cash & equivalents$129.8M+76.2%
Total debt$418.2M+75.8%
Total equity-$826.6M-210%
Total assets$1.3B+0.7%

Cash flow

See full
Operating cash flow-$145.5M-10.5%
CapEx$5.9M+4.7%
Free cash flow-$151.4M-10.3%

Valuation

See full
Market cap$10.7B+70.6%
Enterprise value$10.98B+70.7%
P/S101.1×-225×

Profitability

See full
Operating margin-605.1%-268pp
Net margin-784%-337pp
FCF margin-518.8%-223pp

Returns & leverage

See full
Return on equity-337.6%
Debt / equity2.2×
Current ratio4.2×-1.8×

Where this comes from

Reported directly by Cytokinetics in its filing.

Tagged under the XBRL concept cytk:DebtConversionExpense.

The official record: Cytokinetics’s 10-Q, filed November 5, 2025, on SEC EDGAR. View the filing →

Ask your AI about Cytokinetics's debt conversion expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cytokinetics's debt conversion expense?
Cytokinetics (CYTK) reported debt conversion expense of $121.25M in Q3 2025.
What does debt conversion expense mean?
The accounting cost recognized when debt is converted into company stock.
How do you interpret debt conversion expense?
High values indicate significant dilution and the settlement of debt obligations through equity issuance.
How does debt conversion expense compare across companies?
Standard for companies utilizing convertible debt to fund clinical trials and operations.